Ken Haas JD Overview
- Company
- Aculys
- Primary Position
-
Board Member
- Primary Industry
-
Healthcare
- Active Board Seats
-
2
- Med. Deal Size
-
- Med. Valuation
-
Ken Haas JD General Information
Biography
Mr. Ken Haas served as a Partner at Abingworth Management. He serves as a Board Member at Aculys. He served as a Board Member at Gynesonics. He also serves as a Board Member at Sonitus Medical. He served as a Board Member at eFFECTOR. He was part of the founding management team at IntelliGenetics, from 1992 to 200 and was CEO of Intelli, a publicly traded enterprise software company. At the beginning of his career, he practiced as an attorney in the business and technology group of Heller, Ehrman, White & McAuliffe. He is currently Co-Chair of the Advisory Council of the Neuroscience Institute at Stanford. He received his BA from Harvard College, an MA from the University of Sussex, a J.D. from Harvard Law School, and attended the Advanced Management Program at Harvard Business School. He has been with Abingworth since 2004 and is based in Menlo Park. He served as a Board Member at SFJ Pharmaceuticals.
Contact Information
Address
- 2-14-4 Kita-Aoyama
- Minato-ku
- Tokyo
- Japan
Ken Haas JD Board Seats (2)
| Company | Industry | Ownership Status | Financing Status | Location | Since |
|---|---|---|---|---|---|
| Aculys | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Tokyo, Japan | |
| Effector Therapeutics | Biotechnology | Publicly Held | Formerly VC-backed | Solana Beach, CA |
Ken Haas JD Lead Partner on Deals (10)
Ken Haas JD has been the lead partner on 10 deals. Their latest deal was with Soteria Biotherapeutics, a drug discovery company. The deal was made for on 17-May-2021.
| Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
|---|---|---|---|---|---|---|
| Soteria Biotherapeutics | 17-May-2021 | Early Stage VC (Series A) | Completed | Drug Discovery | San Mateo, CA | |
| Effector Therapeutics | 13-May-2019 | Completed | Biotechnology | Solana Beach, CA | ||
| Gynesonics | 03-Jan-2019 | Completed | Surgical Devices | Redwood City, CA | ||
| Effector Therapeutics | 19-Feb-2016 | Completed | Biotechnology | Solana Beach, CA | ||
| Effector Therapeutics | 20-May-2013 | Completed | Biotechnology | Solana Beach, CA | ||
| SFJ Pharmaceuticals | 19-Apr-2013 | Completed | Drug Discovery | Pleasanton, CA | ||
| Intellikine | 31-Oct-2011 | Completed | Drug Discovery | San Diego, CA | ||
| Pathwork Diagnostics | 06-Oct-2010 | Completed | Diagnostic Equipment | Redwood City, CA | ||
| Pathwork Diagnostics | 04-Sep-2008 | Early Stage VC (Series B) | Completed | Diagnostic Equipment | Redwood City, CA | |
| Intellikine | 31-Dec-2007 | Early Stage VC (Series A) | Completed | Drug Discovery | San Diego, CA |
Ken Haas JD Network (131)
Board Members (59)
| Name | Company | Representing | Location | From |
|---|---|---|---|---|
| Jacques Essinger | Gynesonics | Self | Redwood City, CA | |
| Jay Shepard | Aculys | Aculys | Tokyo, Japan | |
| Effector Therapeutics | Self | Solana Beach, CA | ||
| Protein Mechanics | Self | Mountain View, CA | ||
| Effector Therapeutics | Sectoral Asset Management | Solana Beach, CA |
Portfolio Executives (56)
| Name | Company | Role | Deal date | Location |
|---|---|---|---|---|
| James Wells Ph.D | Soteria Biotherapeutics | Co-Founder & Chairman of Scientific Advisory Board | 17-May-2021 | San Mateo, CA |
| Zachary Hill Ph.D | Soteria Biotherapeutics | Co-Founder, Chief Scientific Officer, Senior Vice President & Board Member | 17-May-2021 | San Mateo, CA |
| Soteria Biotherapeutics | Chief Executive Officer, Senior Vice President, Chief Technical Officer & Board Member | 17-May-2021 | San Mateo, CA | |
| Effector Therapeutics | Executive | 13-May-2019 | Solana Beach, CA | |
| Effector Therapeutics | Chief Medical Officer | 13-May-2019 | Solana Beach, CA |
Fund Team Members (16)
| Name | Investor | Fund | Fund Location |
|---|---|---|---|
| Bali Muralidhar Ph.D | Abingworth | Abingworth Bioventures VII | London, United Kingdom |
| James Abell | Abingworth | Abingworth Bioventures IV | London, United Kingdom |
| Abingworth | London, United Kingdom | ||
| Abingworth | London, United Kingdom | ||
| Abingworth | London, United Kingdom |
Ken Haas JD Affiliated Funds (6)
| Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
|---|---|---|---|---|---|---|---|---|
| Abingworth Bioventures V Co-Invest Growth Equity Fund | Abingworth | Co-Investment | Fully Invested | 2008 | ||||
| Abingworth Bioventures VI | Abingworth | Venture - General | Closed | 2012 | ||||
| Abingworth Bioventures VII | Abingworth | Venture - General | Closed | 2018 | ||||
| Abingworth Clinical Co-Development Co-Investment Fund 2 | Abingworth | Venture Capital - Later Stage | Open | |||||
| Abingworth Bioventures V | Abingworth | Venture - General | Fully Invested | 2007 |
Ken Haas JD FAQs
-
Who is Ken Haas JD?
Mr. Ken Haas served as a Partner at Abingworth Management.
-
How much does Ken Haas JD typically invest?
Ken Haas JD's median deal size is .
-
What is Ken Haas JD’s main position?
Ken Haas JD’s primary position is Board Member.
-
How many active board seats does Ken Haas JD hold?
Ken Haas JD holds 2 board seats including Aculys and Effector Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
